RxDoctor Payments Data

Randall Berinhout, MD

Interventional Pain Medicine · Stockbridge, GANPI 1720031503

Payments from drug & device makers

$1,709in general payments, 2019–2025

Across 71 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Collegium Pharmaceutical, Inc.$153
  • Si-bone, Inc.$147
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$105
  • IBSA Pharma Inc.$68
  • GRT US Holding, Inc.$45
  • plus $150 from 7 others

What the payments were for

  • Food & beverage$1,57092%
  • Education$1398%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,709 in reported general payments places this provider in the 30th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$54,974
Medicare patients
126
Services billed
1,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,543$44,786
RelistorMethylnaltrexone Bromide19$43,585
Xtampza ErOxycodone Myristate49$29,674
OxycontinOxycodone Hcl48$26,960
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,100$23,886
MovantikNaloxegol Oxalate48$21,045
Fentanyl91$12,347
Morphine Sulfate ErMorphine Sulfate350$8,829
LinzessLinaclotide13$6,740
Oxycodone Hcl428$6,538
Gabapentin509$6,507
Pregabalin303$5,764
Lidocaine47$5,536
Lubiprostone26$2,650
Tizanidine Hcl238$2,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$105$43,58519 claims
Collegium Pharmaceutical, Inc.Xtampza Er$153$29,67449 claims
Hikma Pharmaceuticals USAMorphine Sulfate$15$1,32964 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 129 interventional pain medicine providers in Georgia.

Other interventional pain medicine in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →